» Articles » PMID: 33427993

Development of a Symptom Menu to Facilitate Goal Attainment Scaling in Adults with Down Syndrome-associated Alzheimer's Disease: a Qualitative Study to Identify Meaningful Symptoms

Overview
Specialty Health Services
Date 2021 Jan 11
PMID 33427993
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: As life expectancy of people with Down syndrome (DS) increases, so does the risk of Alzheimer's disease (AD). Identifying symptoms and tracking disease progression is especially challenging whenever levels of function vary before the onset of dementia. Goal Attainment Scaling (GAS), an individualized patient-reported outcome, can aid in monitoring disease progression and treatment effectiveness in adults with DS. Here, with clinical input, a validated dementia symptom menu was revised to facilitate GAS in adults living with Down Syndrome-associated Alzheimer's disease (DS-AD).

Methods: Four clinicians with expertise in DS-AD and ten caregivers of adults living with DS-AD participated in semi-structured interviews to review the menu. Each participant reviewed 9-15 goal areas to assess their clarity and comprehensiveness. Responses were systematically and independently coded by two researchers as 'clear', 'modify', 'remove' or 'new'. Caregivers were encouraged to suggest additional items and recommend changes to clarify items.

Results: Median caregiver age was 65 years (range 54-77). Most were female (9/10) with ≥15 years of education (10/10). Adults with DS-AD had a median age of 58 years (range 52-61) and either a formal diagnosis (6/10) or clinical suspicion (4/10) of dementia. The initial symptom menu consisted of 67 symptoms each with 2-12 descriptors (589 total). The clinicians' adaptation yielded 58 symptoms each with 4-17 descriptors (580 total). Of these 580 descriptors, caregivers identified 37 (6%) as unclear; these were reworded, and one goal area (4 descriptors) was removed. A further 47 descriptors and one goal area were added to include caregiver-identified concepts. The final menu contained 58 goal areas, each with 7-17 descriptors (623 total).

Conclusions: A comprehensive symptom menu for adults living with DS-AD was developed to facilitate GAS. Incorporating expert clinician opinion and input from caregivers of adults with DS-AD identified meaningful items that incorporate patient/caregiver perspectives.

Citing Articles

A systematic review of goal attainment scaling implementation practices by caregivers in randomized controlled trials.

Cheema K, Dunn T, Chapman C, Rockwood K, Howlett S, Sevinc G J Patient Rep Outcomes. 2024; 8(1):37.

PMID: 38530578 PMC: 10965877. DOI: 10.1186/s41687-024-00716-w.


Cognitive outcome measures for tracking Alzheimer's disease in Down syndrome.

Fleming V, Hom C, Clare I, Hurd-Thomas S, Krinsky-McHale S, Handen B Int Rev Res Dev Disabil. 2023; 62:227-263.

PMID: 37396708 PMC: 10312212. DOI: 10.1016/bs.irrdd.2022.05.006.


Innovating Therapies for Down Syndrome: An International Virtual Conference of the T21 Research Society.

Hamlett E, Flores-Aguilar L, Handen B, Potier M, Granholm A, Sherman S Mol Syndromol. 2023; 14(2):89-100.

PMID: 37064334 PMC: 10090974. DOI: 10.1159/000526021.


Participation of persons with dementia and their caregivers in research.

Frank L, Jennings L, Petersen R, Majid T, Gilmore-Bykovskyi A, Schicker L J Am Geriatr Soc. 2021; 69(7):1784-1792.

PMID: 34245586 PMC: 8369513. DOI: 10.1111/jgs.17340.

References
1.
Stolee P, Rockwood K, Fox R, Streiner D . The use of goal attainment scaling in a geriatric care setting. J Am Geriatr Soc. 1992; 40(6):574-8. DOI: 10.1111/j.1532-5415.1992.tb02105.x. View

2.
Kiresuk T, Sherman R . Goal attainment scaling: A general method for evaluating comprehensive community mental health programs. Community Ment Health J. 2013; 4(6):443-53. DOI: 10.1007/BF01530764. View

3.
Rockwood K, Richard M, Leibman C, Mucha L, Mitnitski A . Staging dementia from symptom profiles on a care partner website. J Med Internet Res. 2013; 15(8):e145. PMC: 3742393. DOI: 10.2196/jmir.2461. View

4.
Wallen M, OFlaherty S, Waugh M . Functional outcomes of intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial. Arch Phys Med Rehabil. 2007; 88(1):1-10. DOI: 10.1016/j.apmr.2006.10.017. View

5.
Startin C, Rodger E, Fodor-Wynne L, Hamburg S, Strydom A . Developing an Informant Questionnaire for Cognitive Abilities in Down Syndrome: The Cognitive Scale for Down Syndrome (CS-DS). PLoS One. 2016; 11(5):e0154596. PMC: 4859552. DOI: 10.1371/journal.pone.0154596. View